Pyrrolidinyl-pyrrolidinyl compounds

By developing pyrrolidinyl pyrrolidinyl compounds, the adverse reactions and selectivity problems of existing PARP inhibitors during combined use are solved, and the efficient inhibition and low toxicity of PARP1 is achieved, which improves the treatment of BRCA gene defect tumors. efficacy.

CN118908976APending Publication Date: 2024-11-08CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410544826.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-06
Filing Date
2024-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing PARP inhibitors have adverse reactions when used in combination with chemotherapeutic drugs, which limits their application in the treatment of diseases and lacks the selectivity of cells that function normally in BRCA genes, affecting efficacy and toxicity.

Method used

A class of pyrrolidinyl pyrrolidinyl compounds and their stereoisomers or pharmaceutically acceptable salts have been developed, by optimizing their structure to improve selectivity to PARP1, for use as a new PARP inhibitor with better in vivo inhibitory activity and pharmacokinetic properties.

Benefits of technology

This compound has good selectivity for PARP1, significantly inhibits cell proliferation, and has good in vivo pharmacokinetic properties, reduces toxicity to normal cells, and improves the efficacy in the treatment of BRCA gene-deficient tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908976A_ABST
    Figure CN118908976A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemistry, and relates to a pyrrolidinyl pyrrolidinyl compound, in particular to a compound as shown in a formula (IA), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the pharmaceutical composition in treating diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the priority and benefits of the Chinese patent application with application number 202310507032.X, entitled “Pyrrolidino-pyrrolidino compounds”, filed with the State Intellectual Property Office of the People’s Republic of China on May 6, 2023, the entire contents of which are hereby incorporated by reference in their entirety. Technical Field

[0003] The present application relates to pyrrolidinyl and pyrrolidinyl compounds, stereoisomers or pharmaceutically acceptable salts thereof, preparation methods thereof, pharmaceutical compositions containing the compounds, and uses thereof in treating diseases. Background Art

[0004] Poly (ADP-ribose) polymerase [PARP] is a class of cellular nuclear enzymes that catalyze ADP ribosylation. The PARP family consists of 18 members and plays an important role in a wide range of cellular metabolic processes, including DNA damage repair, inflammation regulation, transcriptional regulation, signal transduction, genome stability, cell cycle regulation, and mitosis. PARP1 is the most important PARP enzyme, accounting for 85%-90% of the total PARP activity in cells, and is mainly involved in DNA damage repair. PARP inhibitors can selectively kill tumor cells with homologous recombination repair (HR) function defects caused by BRCA gene defects without affecting the survival of cells with normal BRCA gene function. This phenomenon is called synergistic lethality.

[0005] Since the approval of olaparib in 2014, several PARP inhibitors have been developed and have achieved widespread success. However, the adverse reactions of the drugs limit their ability to be used in combination with chemotherapy drugs. Therefore, PARP inhibitors that improve PARP1 selectivity may have better efficacy and lower toxicity. DETAILED DESCRIPTION OF THE INVENTION

[0007] In one aspect, the present application relates to a compound of formula (IA), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0008]

[0009] in,

[0010] is selected from a single bond or a double bond;

[0011] X 1 Selected from CR a, N or NR a’ ;

[0012] X 2 Selected from CR b or N;

[0013] X 3 and X 4 Each independently selected from CR c or N;

[0014] R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH 2 ) n NR a2 R a3 、-(CH 2 ) n NR a2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 ) n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0015] Y is selected from CR 1 or NR a’ ;

[0016] R a’ is selected from hydrogen, alkyl, cycloalkyl or heterocycloalkyl, wherein the alkyl, cycloalkyl or heterocycloalkyl may be further substituted;

[0017] Or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and together with the atoms to which they are attached form a heterocyclenyl or heteroaryl group, which may be further optionally substituted;

[0018] Or, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and together with the atoms to which they are attached form a heterocyclenyl or heteroaryl group, which may be further optionally substituted;

[0019] R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 ) n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH 2 ) n NR 12 R13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R 13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12 S(O) m R 13 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0020] Or, R 1 and R a and together with the atoms to which they are attached form a cycloalkenyl, heterocycloalkenyl, aryl or heteroaryl group, which may be further optionally substituted;

[0021] Ring A is a heterocyclyl, aryl or heteroaryl group;

[0022] R 2 is selected from the group consisting of deuterium, halogen, nitro, hydroxy, amino, mercapto, oxo, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R 2l 、-(CH 2 ) n C(O)OR2l 、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 ) n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0023] R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 Each is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be further substituted;

[0024] R 3 and R 4are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl or alkynyl, which may be further substituted;

[0025] or R 3 and R 4 Together they form = O;

[0026] p is selected from 0, 1, 2, 3 or 4;

[0027] m is selected from 0, 1 or 2;

[0028] n or n1 is each independently selected from 0, 1, 2, 3 or 4.

[0029] In some embodiments, the compound of formula (IA), its stereoisomers or pharmaceutically acceptable salts thereof are selected from the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof,

[0030]

[0031] in,

[0032] X 1 Selected from CR a or N;

[0033] X 2 Selected from CR b or N;

[0034] X 3 and X 4 Each independently selected from CR c or N;

[0035] R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH2 ) n NR a2 R a3 、-(CH 2 ) n NR a2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 ) n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2 ) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0036] R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 ) n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH 2 ) n NR 12 R13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R 13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12 S(O) m R 13 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0037] Or, R 1 and R a and together with the atoms to which they are attached form a cycloalkenyl, heterocycloalkenyl, aryl or heteroaryl group, which may be further optionally substituted;

[0038] Ring A is a heterocyclyl, aryl or heteroaryl group;

[0039] R 2 is selected from the group consisting of deuterium, halogen, nitro, hydroxy, amino, mercapto, oxo, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R 2l 、-(CH 2 ) n C(O)OR2l 、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 ) n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted;

[0040] R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 Each is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be further substituted;

[0041] R 3 and R 4are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl or alkynyl, which may be further substituted;

[0042] or R 3 and R 4 Together they form = O;

[0043] p is selected from 0, 1, 2, 3 or 4;

[0044] m is selected from 0, 1 or 2;

[0045] n or n1 is each independently selected from 0, 1, 2, 3 or 4.

[0046] In some embodiments, the compound of formula (IA), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

[0047] in,

[0048] is selected from a single bond or a double bond;

[0049] X 1 Selected from CR a , N or NR a’ ;

[0050] X 2 Selected from CR b or N;

[0051] X 3 and X 4 Each independently selected from CR c or N;

[0052] R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH2 ) n NR a2 R a3 、-(CH 2 ) n NR a2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 ) n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2 ) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 The amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further optionally substituted by one or more R aa replace;

[0053] Y is selected from CR 1 or NR a’ ;

[0054] R a’ is selected from hydrogen, alkyl, cycloalkyl or heterocycloalkyl, wherein the alkyl, cycloalkyl or heterocycloalkyl may be further R aa replace;

[0055] Or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and together with the atoms to which they are attached form a heterocycloalkenyl or heteroaryl group, which may optionally be further substituted by R cc replace;

[0056] Or, X 1 Selected from NRa’ , Y is selected from CR 1 , R 1 and R a’ and together with the atoms to which they are attached form a heterocycloalkenyl or heteroaryl group, which may optionally be further substituted by R cc replace;

[0057] R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 ) n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH 2 ) n NR 12 R 13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R 13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12S(O) m R 13 The amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further optionally substituted by one or more R bb replace;

[0058] Or, R 1 and R a and the atoms to which they are attached together form a cycloalkenyl, heterocycloalkenyl, aryl or heteroaryl group, which may be further optionally substituted by one or more R cc replace;

[0059] Ring A is a heterocyclyl, aryl or heteroaryl group;

[0060] R 2 is selected from the group consisting of deuterium, halogen, nitro, hydroxy, amino, mercapto, oxo, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R 2l 、-(CH 2 ) n C(O)OR 2l 、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 ) n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nlR 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 The amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further optionally substituted by one or more R dd replace;

[0061] R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be further optionally substituted by one or more R ee replace;

[0062] R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, mercapto, cyano, alkyl, alkoxy, alkenyl or alkynyl, wherein the amino, alkyl, alkoxy, alkenyl or alkynyl may be further substituted by one or more R ff replace;

[0063] or R 3 and R 4 Together they form = O;

[0064] R aa , R bb , R cc , R dd , R ee and R ff Each is independently selected from deuterium, halogen, hydroxyl, amino, nitro, cyano, mercapto, alkyl, alkoxy, cycloalkyl or heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl may be further substituted with one or more substituents selected from deuterium, halogen, hydroxyl, amino or cyano;

[0065] p is selected from 0, 1, 2, 3 or 4;

[0066] m is each independently selected from 0, 1 or 2;

[0067] n or n1 is each independently selected from 0, 1, 2, 3 or 4.

[0068] In some embodiments, the compound of formula (IA), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

[0069] in,

[0070] is selected from a single bond or a double bond;

[0071] X 1 Selected from CR a , N or NR a’ ;

[0072] X 2 Selected from CR b or N;

[0073] X 3 and X 4 Each independently selected from CR c or N;

[0074] R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH 2 ) n NR a2 R a3 、-(CH 2 ) n NRa2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 ) n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2 ) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl may be further optionally substituted with one or more R aa replace;

[0075] Y is selected from CR 1 or NR a’ ;

[0076] R a’ Selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl or 3-12 membered heterocycloalkyl, the C 1-6 Alkyl, C 3-12 The cycloalkyl or 3-12 membered heterocycloalkyl group may be further optionally substituted by R aa replace;

[0077] Or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R aand the atoms to which they are attached together form a 3-12 membered heterocycloalkenyl or a 5-12 membered heteroaryl, which may be further optionally substituted by R cc replace;

[0078] Or, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a hetero 3-12 membered heterocycloalkenyl or a 5-12 membered heteroaryl, wherein the 3-12 membered heterocycloalkenyl or the 5-12 membered heteroaryl may be further optionally substituted by R cc replace;

[0079] R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, mercapto, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 ) n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH 2 ) n NR 12 R 13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12 S(O) m R 13 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl may be further optionally substituted with one or more R bb replace;

[0080] Or, R 1 and R a Together with the atoms to which they are attached, they form C 4-7 Cycloalkenyl, 4-7 membered heterocycloalkenyl, phenyl or 5-6 membered heteroaryl, the C 4-7 Cycloalkenyl, 4-7 membered heterocycloalkenyl, phenyl or 5-6 membered heteroaryl may be further optionally substituted by one or more R cc replace;

[0081] Ring A is a 5-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0082] R 2 Selected from deuterium, halogen, nitro, hydroxyl, amino, thiol, oxo, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R2l 、-(CH 2 ) n C(O)OR 2l 、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 ) n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 ; The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl may be further optionally substituted with one or more R dd replace;

[0083] R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R23 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 The aryl or 5-12 membered heteroaryl group may be further optionally substituted with one or more R ee replace;

[0084] R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl or C 2-6 Alkynyl, the amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl or C 2-6 The alkynyl group may optionally be further substituted with one or more R ff replace;

[0085] or R 3 and R 4 Together they form = O;

[0086] R aa , R bb , R cc , R dd , R ee and R ff are each independently selected from deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl may be further optionally substituted with one or more substituents selected from deuterium, halogen, hydroxyl, amino or cyano;

[0087] p is selected from 0, 1, 2, 3 or 4;

[0088] m is each independently selected from 0, 1 or 2;

[0089] n or n1 is each independently selected from 0, 1, 2, 3 or 4.

[0090] In some embodiments, Select from double bonds.

[0091] In some embodiments, Select from single bonds.

[0092] In some embodiments, Selected from double bonds, X 1 Selected from CR a or N, Y selected from CR 1 .

[0093] In some embodiments, R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH 2 ) n NR a2 R a3 、-(CH 2 ) n NR a2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 )n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2 ) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R aa replace.

[0094] In some embodiments, R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R al 、-(CH 2 ) n OR al 、-(CH 2 ) n C(O)R al 、-(CH 2 ) n C(O)OR al 、-(CH 2 ) n S(O) m R al 、-(CH 2 ) n NR a2 R a3、-(CH 2 ) n NR a2 C(O)OR a3 、-(CH 2 ) n NR a2 C(O)(CH 2 ) nl R a3 、-(CH 2 ) n NR a2 C(O)NR a2 R a3 、-(CH 2 ) n C(O)NR a2 (CH 2 ) nl R a3 、-OC(R al R a2 ) n (CH 2 ) nl R a3 or -(CH 2 ) n NR a2 S(O) m R a3 , the amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R aa replace.

[0095] In some embodiments, X 1 Selected from CR a .

[0096] In some embodiments, R a Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the amino, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R aa replace.

[0097] In some embodiments, R aSelected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the amino, C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R aa replace.

[0098] In some embodiments, R aa Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

[0099] In some embodiments, R aa Selected from deuterium, halogen or hydroxyl.

[0100] In some embodiments, R aa Selected from F.

[0101] In some embodiments, R a Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from deuterium, halogen or hydroxyl.

[0102] In some embodiments, R a Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from halogen.

[0103] In some embodiments, R a is selected from hydrogen or halogen.

[0104] In some embodiments, R a Selected from hydrogen or F.

[0105] In some embodiments, R a Selected from hydrogen.

[0106] In some embodiments, X 1 Selected from CH.

[0107] In some embodiments, X 1 Selected from N.

[0108] In some embodiments, X 2 Selected from CR b .

[0109] In some embodiments, R b Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the amino, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R aa replace.

[0110] In some embodiments, R b Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the amino, C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R aa replace.

[0111] In some embodiments, R b Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from deuterium, halogen or hydroxyl.

[0112] In some embodiments, R b Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from halogen.

[0113] In some embodiments, R b is selected from hydrogen or halogen.

[0114] In some embodiments, R b Selected from hydrogen or F.

[0115] In some embodiments, R b Selected from hydrogen.

[0116] In some embodiments, X 2 is selected from CH or C(F).

[0117] In some embodiments, X 2 Selected from N.

[0118] In some embodiments, R c Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the amino, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R aa replace.

[0119] In some embodiments, R c Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the amino, C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R aa replace.

[0120] In some embodiments, R c Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from deuterium, halogen or hydroxyl.

[0121] In some embodiments, R c Selected from hydrogen, halogen or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R aa In some embodiments, R aa Selected from halogen.

[0122] In some embodiments, R c is selected from hydrogen or halogen.

[0123] In some embodiments, R c Selected from hydrogen or F.

[0124] In some embodiments, R c Selected from hydrogen.

[0125] In some embodiments, X 3 and X 4 are each independently selected from CH or N.

[0126] In some embodiments, X 3 is selected from CH, C(F) or N.

[0127] In some embodiments, X 1 , X 2 , X 3 and X 4 1, 2, 3, or 4 of them are selected from CH.

[0128] In some embodiments, X 1 , X 2 , X 3 and X 4 1, 2, 3, or 4 of them are selected from N.

[0129] In some embodiments, X 1 , X 2 , X 3 and X 4 There is 1 selected from N.

[0130] In some embodiments, X 1 Select from N, X 2 , X 3 and X 4 is selected from CH, C(F) or N.

[0131] In some embodiments, X 2 Select from N, X 1 , X 3 and X 4 is selected from CH, C(F) or N.

[0132] In some embodiments, X 3 Select from N, X 1 , X 2 and X 4 is selected from CH, C(F) or N.

[0133] In some embodiments, X 4 Select from N, X 1 , X 2 and X 3 is selected from CH, C(F) or N.

[0134] In some embodiments, X 1 Selected from CH, X 2 Selected from CH, X 3 Selected from CH, X 4 Selected from CH.

[0135] In some embodiments, X 1 Select from N, X 2 Selected from CH, X 3Selected from CH, X 4 Selected from CH.

[0136] In some embodiments, X 1 Select from N, X 2 Selected from C(F), X 3 Selected from CH, X 4 Selected from CH.

[0137] In some embodiments, X 1 Selected from CH, X 2 Selected from CH, X 3 Select from N, X 4 Selected from CH.

[0138] In some embodiments, X 1 Selected from CH, X 2 Selected from CH, X 3 Selected from CH, X 4 Selected from N.

[0139] In some embodiments, X 1 Selected from CH, X 2 Selected from C(F), X 3 Selected from CH, X 4 Selected from CH.

[0140] In some embodiments, X 1 Selected from CH, X 2 Selected from CH, X 3 Selected from C(F), X 4 Selected from C(F).

[0141] In some embodiments, Y is selected from CR 1 .

[0142] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a 5-6 membered heterocycloalkenyl or a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkenyl or the 5-6 membered heteroaryl may be further optionally substituted by R cc replace.

[0143] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a 5-6 membered heteroaryl group, which may be further optionally substituted by one or more R ccreplace.

[0144] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a 5-membered heteroaryl group, which may optionally be further substituted with one or more R cc replace.

[0145] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a 5-membered heteroaryl group.

[0146] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a pyrrolyl, pyrazolyl or imidazolyl.

[0147] In some embodiments, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached form

[0148] In some embodiments, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a 5-6 membered heterocycloalkenyl or a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkenyl or the 5-6 membered heteroaryl may be further optionally substituted by R cc replace.

[0149] In some embodiments, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a 5-6 membered heteroaryl group, which may be further optionally substituted by one or more R cc replace.

[0150] In some embodiments, X1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a 5-membered heteroaryl group, which may optionally be further substituted with one or more R cc replace.

[0151] In some embodiments, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a 5-membered heteroaryl group.

[0152] In some embodiments, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a pyrrolyl, pyrazolyl or imidazolyl.

[0153] In some embodiments, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached form

[0154] In some embodiments, R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, mercapto, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 ) n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH2 ) n NR 12 R 13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R 13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12 S(O) m R 13 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R bb replace.

[0155] In some embodiments, R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, mercapto, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R 1l 、-(CH 2 ) n OR 1l 、-(CH 2 )n C(O)R 1l 、-(CH 2 ) n C(O)OR 1l 、-(CH 2 ) n S(O) m R 1l 、-(CH 2 ) n NR 12 R 13 、-(CH 2 ) n NR 12 C(O)OR 13 、-(CH 2 ) n NR 12 C(O)(CH 2 ) nl R 13 、-(CH 2 ) n NR 12 C(O)NR 12 R 13 、-(CH 2 ) n C(O)NR 12 (CH 2 ) nl R 13 、-OC(R 1l R 12 ) n (CH 2 ) nl R 13 or -(CH 2 ) n NR 12 S(O) m R 13 , the amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R bb replace.

[0156] In some embodiments, R 1 Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the amino, C 1-3Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R bb replace.

[0157] In some embodiments, R 1 Selected from C 1-3 Alkyl or C 3-6 Cycloalkyl, the C 1-3 Alkyl or C 3-6 The cycloalkyl group may be further optionally substituted with one or more R bb replace.

[0158] In some embodiments, R bb Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

[0159] In some embodiments, R bb Selected from deuterium, halogen or hydroxyl.

[0160] In some embodiments, R bb Selected from F.

[0161] In some embodiments, R 1 is selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl, wherein the methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl or morpholinyl may be further substituted by one or more R bb In some embodiments, R bb Selected from deuterium, halogen or hydroxyl.

[0162] In some embodiments, R 1 is selected from methyl, ethyl or cyclopropyl, wherein the methyl, ethyl or cyclopropyl group may be further optionally substituted by one or more R bb In some embodiments, R bb Selected from F.

[0163] In some embodiments, R 1 Selected from methyl, trifluoromethyl, ethyl, cyclopropyl.

[0164] In some embodiments, R 1and R a Together with the atoms to which they are attached, they form C 5-6 Cycloalkenyl, 5-6 membered heterocycloalkenyl, phenyl or 5-6 membered heteroaryl, the C 5-6 Cycloalkenyl, 5-6 membered heterocycloalkenyl, phenyl or 5-6 membered heteroaryl may be further optionally substituted by one or more R cc In some embodiments, R 1 and R a Together with the atoms to which they are attached, they form C 5-6 Cycloalkenyl, the C 5-6 The cycloalkenyl group may be further optionally substituted with one or more R cc In some embodiments, R cc Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

[0165] In some embodiments, R cc Selected from deuterium, halogen or hydroxyl.

[0166] In some embodiments, R cc Selected from F.

[0167] In some embodiments, R 1 and R a and the atoms to which they are attached together form a cyclopentenyl or cyclohexenyl group, which may optionally be further substituted by one or more R cc In some embodiments, R cc Selected from deuterium, halogen or hydroxyl.

[0168] In some embodiments, R 1 With R a and the atoms to which they are attached form Said Optionally, it may be further represented by one or more R cc In some embodiments, R cc Selected from F.

[0169] In some embodiments, R 1 With R a and the atoms to which they are attached form

[0170] In some embodiments, Ring A is a 6-10 membered heterocyclyl, C 6-10 Aryl or 5-10 membered heteroaryl.

[0171] In some embodiments, ring A is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heteroaryl and 6-membered heteroaryl, 6-membered heteroaryl and 6-membered heteroaryl, 6-membered heteroaryl and 6-membered heterocyclyl, 6-membered heteroaryl and 5-membered heterocyclyl, phenyl and 5-membered heterocyclyl, phenyl and 6-membered heteroaryl or phenyl and 6-membered heterocyclyl, the heteroatoms in the heterocyclyl and heteroaryl are independently selected from nitrogen, oxygen or sulfur, and the number of heteroatoms is independently 1, 2 or 3.

[0172] In some embodiments, Ring A is a 5-6 membered heteroaryl group containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0173] In some embodiments, Ring A is a 6-membered heteroaryl containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0174] In some embodiments, Ring A is furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.

[0175] In some embodiments, Ring A is a 6-membered heteroaryl containing 1 or 2 nitrogen heteroatoms.

[0176] In some embodiments, Ring A is pyridinyl.

[0177] In some embodiments, R 2 Selected from deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R 2l 、-(CH 2 ) n C(O)OR 2l 、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 )n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R dd replace.

[0178] In some embodiments, R 2 Selected from deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH 2 ) n R 2l 、-(CH 2 ) n OR 2l 、-(CH 2 ) n C(O)R 2l 、-(CH 2 ) n C(O)OR 2l、-(CH 2 ) n S(O) m R 2l 、-(CH 2 ) n NR 22 R 23 、-(CH 2 ) n NR 22 C(O)OR 23 、-(CH 2 ) n NR 22 C(O)(CH 2 ) nl R 23 、-(CH 2 ) n NR 22 C(O)NR 22 R 23 、-(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 、-OC(R 2l R 22 ) n (CH 2 ) nl R 23 or -(CH 2 ) n NR 22 S(O) m R 23 , the amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R dd replace.

[0179] In some embodiments, R 2 Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -(CH 2 ) n C(O)OR 2l 、-(CH 2 ) n NR a2C(O)(CH 2 ) nl R 23 or -(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 , the amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R dd replace.

[0180] In some embodiments, R 2 Selected from halogen, C 1-3 Alkyl, C 1-3 Alkoxy or -(CH 2 ) n C(O)NR 22 (CH 2 ) nl R 23 , the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R dd replace.

[0181] In some embodiments, R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 are each independently selected from hydrogen, deuterium or C 1-3 Alkyl, the C 1-3 The alkyl group may optionally be further substituted with one or more R ee replace.

[0182] In some embodiments, R dd or R ee are each independently selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

[0183] In some embodiments, R dd or R eeEach is independently selected from deuterium, halogen or hydroxyl.

[0184] In some embodiments, R dd or R ee are each independently selected from F.

[0185] In some embodiments, R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 Each is independently selected from H or methyl.

[0186] In some embodiments, R 2 Selected from halogen, C 1-3 Alkyl, C 1-3 Alkoxy or -C(O)NR 22 R 23 , the C 1-3 Alkyl or C 1-3 Optionally, the alkoxy group may be further substituted with one or more deuterium, halogen or hydroxyl groups.

[0187] In some embodiments, R 2 Selected from halogen, C 1-3 Alkyl, C 1-3 Alkoxy or -C(O)NH(CH 3 ), the C 1-3 Alkyl or C 1-3 Optionally, the alkoxy group may be further substituted with one or more deuterium, halogen or hydroxyl groups.

[0188] In some embodiments, R 2 Selected from fluorine, methyl, -OCH 3 or -C(O)NHCH 3 .

[0189] In some embodiments, R 2 Selected from -C(O)NHCH 3 .

[0190] In some embodiments, R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl or C 2-4 Alkynyl, the amino, C 1-3 Alkyl, C 1-3 Alkoxy, C2-4 Alkenyl or C 2-4 The alkynyl group may optionally be further substituted with one or more R ff replace.

[0191] In some embodiments, R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, the amino, C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R ff replace.

[0192] In some embodiments, R ff Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

[0193] In some embodiments, R ff Selected from deuterium, halogen or hydroxyl.

[0194] In some embodiments, R ff Selected from F.

[0195] In some embodiments, R 3 and R 4 Each is independently selected from hydrogen, deuterium, hydroxy, amino, methyl or methoxy.

[0196] In some embodiments, R 3 and R 4 are each independently selected from hydrogen or deuterium.

[0197] In some embodiments, R 3 and R 4 are selected from hydrogen.

[0198] In some embodiments, p is selected from 0, 1, 2, 3 or 4.

[0199] In some embodiments, p is selected from 1, 2 or 3.

[0200] In some embodiments, p is selected from 1 or 2.

[0201] In some embodiments, p is selected from 1.

[0202] In some embodiments, m is selected from 1 or 2.

[0203] In some embodiments, n or n1 are each independently selected from 0, 1 or 2.

[0204] In some embodiments, n or n1 are each independently selected from 0 or 1.

[0205] In some embodiments, the structural unit Selected from

[0206] In some embodiments, the structural unit Selected from

[0207] In some embodiments, the structural unit Selected from

[0208] In some embodiments, the structural unit Selected from

[0209] In some embodiments, the structural unit Selected from

[0210] In some embodiments, the structural unit Selected from

[0211] In some embodiments, the structural unit Selected from

[0212] In some embodiments, the compound of formula (IA) of the present application, its stereoisomers or pharmaceutically acceptable salts thereof are selected from the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), its stereoisomers or pharmaceutically acceptable salts thereof,

[0213]

[0214]

[0215] in,

[0216] R 1 , R 2 , X 1 , X 2 , X 3 , X 4 and n are as defined in this application;

[0217] Ring B is selected from 5-6 membered heteroaryl, the 5-6 membered heteroaryl is optionally substituted by one or more R cc replace.

[0218] In some embodiments, Ring B is selected from 5-membered heteroaryl.

[0219] In some embodiments, Ring B is selected from pyrrolyl, pyrazolyl, or imidazolyl.

[0220] In some embodiments, Ring B is selected from

[0221] In some embodiments, the compound of formula (IA) of the present application, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the compound of formula (IIA), the compound of formula (IIIA), the compound of formula (IVA), the compound of formula (VA), its stereoisomer or a pharmaceutically acceptable salt thereof:

[0222]

[0223] in,

[0224] R 1 , R 2 , X 1 , X 2 , X 3 , X 4 and n are as defined in this application;

[0225] Ring B is as described above for the compound of formula (IV) and the compound of formula (V).

[0226] In some embodiments, the present application comprises the above-defined variables and embodiments thereof, and any combination thereof.

[0227] In some embodiments, the compound of the present application, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the following compounds, its stereoisomer or a pharmaceutically acceptable salt thereof:

[0228]

[0229]

[0230] In some embodiments, the compound of the present application, its stereoisomer or a pharmaceutically acceptable salt thereof is selected from the following compounds, its stereoisomer or a pharmaceutically acceptable salt thereof:

[0231]

[0232]

[0233] On the other hand, the present application provides a pharmaceutical composition, which comprises the above-mentioned compound of the present application, its stereoisomer or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition of the present application further comprises a pharmaceutically acceptable excipient.

[0234] On the other hand, the present application provides a method for treating PARP-related diseases in mammals, comprising administering a therapeutically effective amount of the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment.

[0235] On the other hand, the present application provides the use of the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a drug for treating PARP-related diseases.

[0236] On the other hand, the present application provides the use of the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt, or its pharmaceutical composition in treating PARP-related diseases.

[0237] On the other hand, the present application provides the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt, or pharmaceutical composition thereof for treating diseases related to PARP.

[0238] In some embodiments, the PARP-related disease is selected from a tumor, a cancer, an ischemic disease, or a neurodegenerative disease.

[0239] In some embodiments, the PARP-related disease is preferably a PARP1-related disease.

[0240] The compounds of the present application have good selectivity for PARP1 polymerase, good inhibitory activity against cell proliferation, good in vivo inhibitory activity, and good in vivo pharmacokinetic properties.

[0241] definition

[0242] Unless otherwise specified, the following terms used in this application have the following meanings. A particular term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0243] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced, and oxo will not occur on an aromatic group.

[0244] The term "optionally" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes both the occurrence of the event or situation and the non-occurrence of the event or situation. For example, ethyl is "optionally" substituted with halogen, which means that the ethyl group may be unsubstituted (CH 2 CH 3 ), monosubstituted (such as CH 2 CH 2 F), polysubstituted (such as CHFCH 2 F, CH 2 CHF 2 etc.) or completely replaced (CF 2 CF 3 ). It will be understood by those skilled in the art that for any group comprising one or more substituents, no substitution or substitution pattern will be introduced that is sterically impossible to exist and / or cannot be synthesized.

[0245] The “substituents” described herein include, but are not limited to, the terms “alkyl”, “alkoxy”, “alkylthio”, “cycloalkyloxy”, “heteroalkyl”, “alkenyl”, “alkynyl”, “cycloalkenyl”, “cycloalkyl”, “cycloalkynyl”, “heterocycloalkyl”, “heterocycloalkenyl”, “heterocyclyl”, “aryl”, “heteroaryl”, “alkylene”, etc., and corresponding non-limiting or exemplary groups, wherein some non-limiting examples of the “substituents” include protium, deuterium, tritium, -OH, -SH, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, halo-alkyl, cycloalkyl, halo-cycloalkyl, alkenyl, halo-alkenyl, cycloalkenyl, halo-cycloalkenyl, alkynyl, halo-alkynyl, cycloalkynyl, halo- alkyl, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkyl, heteroarylalkoxy, heteroarylalkylthio, heterocyclyl, heterocyclyloxy, heterocyclylthio, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylalkylthio, acyl, acyloxy, carbamate group, amide group, urea group, epoxy group and ester group, etc., which are optionally substituted by one or more substituents selected from the following: oxo, hydroxyl, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C(O)NH 2 , -C(O)NH-alkyl, -C(O)N(alkyl) 2 , -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O) 2 -alkyl, -S(O)2 NH 2 、-S(O) 2 NH-alkyl, -S(O) 2 N(alkyl) 2 , cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, aryl, arylalkyl or aryloxy.

[0246] As used herein, "one or more" refers to an integer from one to ten. For example, "one or more" refers to one, two, three, four, five, six, seven, eight, nine or ten; or, "one or more" refers to one, two, three, four, five or six; or, "one or more" refers to one, two or three. It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and / or cannot be synthesized will be introduced.

[0247] In this article, C m-n , means that the moiety has an integer number of carbon atoms in a given range. For example, "C 1-6 ” means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.

[0248] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 2 R's, each R has an independent choice.

[0249] When a substituent's bond crosses two atoms in a ring, the substituent may be bonded to any atom in the ring. It means that it can be substituted at any position on the cyclohexyl group or cyclohexadiene.

[0250] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0251] The term "hydroxy" refers to an -OH group.

[0252] The term "amino" refers to -NH 2 Group.

[0253] The term "mercapto" refers to a -SH group.

[0254] The term "cyano" refers to a -CN group.

[0255] The term "nitro" refers to -NO 2 Group.

[0256] The term "alkyl" refers to a group of the formula C n H 2n+1 The alkyl group may be straight chain or branched. For example, the term "C 1-6 The term "alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl and alkylthio has the same definition as above.

[0257] The term "alkoxy" refers to an -O-alkyl group.

[0258] The term "alkylamino" refers to an -NH-alkyl group.

[0259] The term "dialkylamino" refers to -N(alkyl) 2 .

[0260] The term "alkenyl" refers to a linear or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms having at least one double bond. Non-limiting examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, etc.

[0261] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. Non-limiting examples of alkynyl include, but are not limited to, ethynyl (-C≡CH), 1-propynyl (-C≡C-CH 3 ), 2-propynyl (-CH 2 -C≡CH), 1,3-butadiynyl (-C≡CC≡CH), etc.

[0262] The term "cycloalkyl" refers to a fully saturated carbocyclic ring that can exist as a monocyclic, bridged or spirocyclic ring. Unless otherwise indicated, the carbocyclic ring is typically a 3 to 10-membered ring; preferably a 3 to 6-membered ring. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, and the like.

[0263] The term "cycloalkenyl" refers to a partially saturated carbon ring that can exist as a monocyclic, spirocyclic or bridged ring. Unless otherwise indicated, the cycloalkenyl group is C 3-12 Cycloalkenyl, preferably C 3-10 Cycloalkenyl, more preferably C 3-7 Cycloalkenyl. Examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cycloheptenyl, and cyclooctenyl. Cycloalkenyl may be substituted with one or more substituents as described herein.

[0264] The term "heterocycloalkyl" refers to a cyclic group that is fully saturated and can exist as a monocyclic, bridged or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3 to 10-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, silicon, phosphorus, oxygen and / or nitrogen, preferably a 3 to 8-membered ring. Examples of 3-membered heterocycloalkyl include, but are not limited to, oxirane, thioethane, and cyclonitroethane. Non-limiting examples of 4-membered heterocycloalkyl include, but are not limited to, azetidinyl, oxadiazolyl, and thiadinyl. Examples of 5-membered heterocycloalkyl include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, and tetrahydropyrazolyl. Examples of 6-membered heterocycloalkyl include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,3-dithianyl, and 1,4-dithianyl. Examples of 7-membered heterocycloalkyl include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Preferably, it is a monocyclic heterocycloalkyl with 4 or 6 ring atoms.

[0265] The term "heterocycloalkenyl" includes cycloalkenyl groups that one or more carbon atoms are replaced by heteroatoms, specifically for example, cycloalkenyl groups that are independently selected from the heteroatoms of sulphur, silicon, phosphorus, oxygen and / or nitrogen at most 3 carbon atoms, at most 2 carbon atoms in one embodiment, and 1 carbon atom in another embodiment, with the condition that at least one cycloalkenyl carbon-carbon double bond is retained. The cyclic group that can exist with monocycle, bridged ring or spirocycle can be 3 to 12 rings (for example 5 yuan, 6 yuan or 7 yuan ring). The example of heterocycloalkenyl includes but is not limited to dihydropyrrolyl, dihydrofuranyl, tetrahydropyridyl, tetrahydroazepine base or azaspirocyclooctene.

[0266] The term "heterocyclic group" refers to a ring that is fully saturated or partially saturated (but not fully unsaturated heteroaromatic), and can exist as a monocyclic, bridged or spirocyclic ring. Unless otherwise indicated, the heterocyclic ring is typically a 3 to 10-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, silicon, phosphorus, oxygen and / or nitrogen, or a 5 to 8-membered ring, or a 5 or 6-membered ring. Non-limiting examples of heterocyclyl groups include, but are not limited to, oxirane, tetrahydrofuranyl, dihydrofuranyl, 3,4-dihydropyranyl, 3,6-dihydropyranyl, pyrrolidinyl, N-methylpyrrolidinyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothiophenyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and the like.

[0267] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π electron system. For example, an aryl group may have 6-20 carbon atoms, 6-14 carbon atoms, or 6-12 carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and 1,2,3,4-tetrahydronaphthalene, etc.

[0268] The term "heteroaryl" refers to a monocyclic or fused polycyclic system containing at least one ring atom selected from sulfur, silicon, phosphorus, oxygen and / or nitrogen, the remaining ring atoms being C, and having at least one aromatic ring. Preferred heteroaryl groups have a single 5 to 8-membered ring, especially a single 5 to 6-membered ring, or multiple fused rings containing 6 to 14, especially 6 to 10 ring atoms. Non-limiting examples of heteroaryl include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, etc.

[0269] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0270] (i) inhibiting a disease or disease state, i.e. arresting its development;

[0271] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.

[0272] The term "therapeutically effective amount" means an amount of the compound of the present application that (i) treats a specific disease, condition, or disorder described herein, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder described herein, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of the compound of the present application that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and the present disclosure.

[0273] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0274] As the pharmaceutically acceptable salt, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.

[0275] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or their salts and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.

[0276] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0277] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to".

[0278] The compounds and intermediates of the present application can also exist in different tautomeric forms, and all such forms are included in the scope of the present application. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also referred to as prototransfer tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. The specific example of a proton tautomer is an imidazole moiety, in which a proton can migrate between two ring nitrogens. Valence tautomers include interconversions by the reorganization of some bonding electrons.

[0279] Unless specifically stated otherwise, singular terms include plural terms and plural terms include singular terms. Unless specifically stated otherwise, the word "a" or "an" means "at least one" or "at least one".

[0280] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention.

[0281] Unless otherwise specified, the key is a solid wedge. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond. and straight dashed key Indicates the relative configuration of a stereocenter.

[0282] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, separation of enantiomers and diastereomers is usually accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (e.g., carbamate formation from an amine).

[0283] The present application also includes isotopically labeled compounds of the present application that are identical to those described herein, but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.

[0284] Certain isotope-labeled compounds of the present application (e.g. 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. Positron emitting isotopes such as 15 O. 13 N. 11 C and 18F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present application can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0285] In addition, the use of heavier isotopes such as deuterium (i.e. 2 H)) substitution can provide certain therapeutic advantages (e.g., increased in vivo half-life or reduced dosage requirements) resulting from higher metabolic stability, and therefore may be preferred in certain situations, wherein deuterium substitution can be partial or complete, partial deuterium substitution means that at least one hydrogen is replaced by at least one deuterium. Exemplary deuterated compounds are shown below, but are not limited thereto.

[0286] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0287] Typical routes of administration of the compounds of the present application or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0288] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.

[0289] In all methods of administration of the compounds of formula I described herein, the dosage administered is 0.01 to 200 mg / kg body weight per day in single or divided doses.

[0290] The compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0291] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.

[0292] An important consideration in synthetic route planning in the art is to select a suitable protecting group for a reactive functional group (such as the amino group in this application). For example, reference may be made to Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc. All references cited in this application are incorporated herein in their entirety.

[0293] In some embodiments, the compounds of the present disclosure can be prepared by those skilled in the art of organic synthesis with reference to the following routes:

[0294]

[0295] Among them, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 and R 23 The definition of is as above. DETAILED DESCRIPTION

[0296] For the sake of clarity, the present invention is further described with examples, but the examples are not intended to limit the scope of the present application. It will be apparent to those skilled in the art that various changes and modifications are made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention. All reagents used in the present application are commercially available and can be used without further purification.

[0297] The compounds of the present application can be prepared by those skilled in the art of organic synthesis with reference to the routes or methods of the following examples, and the obtained compounds can be characterized by known instruments or methods, including but not limited to mass spectrometry, nuclear magnetic resonance, etc.

[0298] This application uses the following abbreviations:

[0299] Bn represents benzyl.

[0300] Example 1: Preparation of Compound 1

[0301]

[0302] Step A: Preparation of Compound 1-1

[0303] In a 50 mL single-mouth bottle, (3aR, 6aR)-hexahydropyrrolo[3,2-b]pyrrole-1(2H)-carboxylic acid benzyl ester (0.867 g), 1,4-dioxane (30 mL), 5-bromopicolinic acid methyl ester (0.8 g), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.155 g), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (0.086 g) and cesium carbonate (2.413 g) were added in sequence, and the reaction system was transferred to 105°C and stirred overnight under nitrogen protection. After the reaction was completed, the compound 1-1 was obtained by extraction, drying, concentration, and column chromatography (petroleum ether: ethyl acetate = 1:1).

[0304] MS (ESI, [M+H] + )m / z:382.28.

[0305] Step B: Preparation of Compound 1-2

[0306] Compound 1-1 (1.05 g) and 30% methylamine ethanol solution (30 mL) were added to a 50 mL single-mouth bottle in sequence, and after the addition, the atmosphere was replaced with nitrogen and reacted at room temperature overnight. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain compound 1-2.

[0307] MS (ESI, [M+H] + )m / z:381.30.

[0308] Step C: Preparation of Compound 1-3

[0309] In a 100 mL single-necked bottle, compound 1-2 (1.0 g), anhydrous ethanol (25 mL), 10% palladium carbon by mass, and glacial acetic acid (2 mL) were added in sequence. After the addition, the hydrogen gas was replaced and the reaction was carried out at room temperature overnight. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain compound 1-3.

[0310] MS (ESI, [M+H] + )m / z:247.23.

[0311] Step D: Preparation of Compound 1

[0312] In a 50 mL single-mouth bottle, compound 1-3 (0.122 g), acetonitrile (20 mL), 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxaldehyde (0.1 g), triethylamine (0.15 g), tetraisopropyl titanate (0.141 g) and sodium triacetoxyborohydride (0.21 g) were added in sequence, and the reaction system was stirred overnight at room temperature under nitrogen protection. After the reaction was completed, compound 1 was obtained by extraction, drying, concentration, and column chromatography (dichloromethane: methanol = 20:1).

[0313] 1 H NMR (500 MHz, DMSO-d 6 )δ11.79(s,1H),8.41(d,J=1.8Hz,1H),8.29(q,J=4.9Hz,1H),7.90(d,J=2.8Hz,1H),7.80(d,J=8.6H z,1H),7.74(s,1H),7.62(s,1H),7.00(dd,J=8.8,2.8Hz,1H),4.48–4.23(m,1H),4.09(d,J=13.8Hz,1 H),3.55–3.38(m,3H),3.37–3.34(m,1H),2.86–2.80(m,1H),2.78(d,J=4.8Hz,3H),2.56–2.52(m,2H ),2.36–2.21(m,2H),2.11–2.01(m,1H),1.91–1.79(m,1H),1.41–1.30(m,1H),1.18(t,J=7.4Hz,3H).

[0314] HRMS (ESI, [M+H] + )m / z:433.2345.

[0315] Example 2: Preparation of Compound 2

[0316]

[0317] Step A: Preparation of Compound 2-1

[0318] Referring to the method of step D of Example 1, 3-ethyl-2-methoxyquinoline-7-carbaldehyde was reacted with compound 1-3 to prepare compound 2-1.

[0319] MS (ESI, [M+H] + )m / z:446.35.

[0320] Step B: Preparation of Compound 2

[0321] Compound 2-1 (250 mg), 1,4-dioxane (10 mL), and 1,4-dioxane hydrochloride solution (1.5 mL, 4 mol / L) were added to a 50 mL single-mouth bottle in sequence. After the addition, the oil bath was heated to 60 ° C for 3 h in nitrogen replacement. After the reaction was completed, compound 2 was obtained by freeing, extraction, drying, concentration, and column chromatography (dichloromethane: methanol = 20:1).

[0322] 1 H NMR (500 MHz, DMSO-d 6 )δ11.62(s,1H),8.29(q,J=4.8Hz,1H),7.89(d,J=2.8Hz,1H),7.80(d,J=8.6Hz,1H),7.68(s,1H),7.55(d,J=7.9Hz,1 H),7.28(s,1H),7.12(dd,J=8.0,1.5Hz,1H),6.99(dd,J=8.8,2.8Hz,1H),4.52–4.27(m,1H),4.03(d,J=13.5Hz,1H),3 .54–3.47(m,1H),3.47–3.38(m,2H),3.33–3.31(m,1H),3.30–3.24(m,1H),2.85–2.79(m,1H),2.78(d,J=4.8Hz,3H), 2.49–2.44(m,1H),2.35–2.19(m,2H),2.07–1.97(m,1H),1.90–1.78(m,1H),1.41–1.30(m,1H),1.16(t,J=7.4Hz,3H).

[0323] HRMS (ESI, [M+H] + )m / z:432.2401.

[0324] Example 3: Preparation of Compound 3

[0325]

[0326] Step A: Preparation of compound 3-1

[0327] Referring to the method of step A of Example 1, compound 3-1 was prepared by reacting methyl 5-bromo-6-fluoropicolinate with tert-butyl (3aR, 6aR)-hexahydropyrrolo[3,2-b]pyrrole-1(2H)-carboxylate.

[0328] MS (ESI, [M+H] + )m / z:366.06.

[0329] Step B: Preparation of compound 3-2

[0330] Referring to the method of step B of Example 1, compound 3-1 was reacted with methylamine hydrochloride to prepare compound 3-2.

[0331] MS (ESI, [M+H] + )m / z:365.09.

[0332] Step C: Preparation of compound 3-3

[0333] Compound 3-2 (360 mg), dichloromethane (10 mL) and trifluoroacetic acid (1368 mg) were added to a 50 mL single-mouth bottle in sequence. After the addition, the mixture was stirred at room temperature for 1 hour. After the reaction was complete, the solvent and excess trifluoroacetic acid were removed by concentration, and the obtained oil was directly used for the next step reaction.

[0334] MS (ESI, [M+H] + )m / z:265.04.

[0335] Step D: Preparation of Compound 3-4

[0336] In a 100mL single-mouth bottle, 5-bromo-2-methylpyridin-3-amine (11g), N,N-dimethylformamide (110mL), 1-methylimidazole (29.0g), 3,3,3-trifluoropropionic acid (9.79g) and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (41.3g) were added in sequence, and the mixture was stirred at room temperature for 12 hours under nitrogen protection. After the reaction was complete, saturated sodium bicarbonate aqueous solution (100mL) was added to the reaction system to adjust the pH to weak alkalinity, and ethyl acetate (100mL*3) was used for extraction, and the organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 10.28g of compound 3-4.

[0337] MS (ESI, [M+H] + )m / z:297.06.

[0338] Step E: Preparation of Compound 3-5

[0339] Compound 3-4 (17.47 g), anhydrous dioxane (200 mL) and selenium oxide (26.1 g) were added to a 50 mL single-mouth bottle in sequence, and the mixture was placed at 80°C for 3 hours under nitrogen protection. After the reaction was complete, the insoluble solid was removed by diatomaceous earth filtration, the filter cake was washed with EA, and the organic phase was combined, dried, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain 5.34 g of compound 3-5.

[0340] MS (ESI, [MH] - )m / z:309.02.

[0341] Step F: Preparation of Compound 3-6

[0342] Compound 3-5 (5.34 g), anhydrous N,N-dimethylformamide (60 mL) and cesium carbonate (11.19 g) were added to a 50 mL single-mouth bottle in sequence, and the mixture was placed at 60°C for 2 hours under nitrogen protection. After the reaction was complete, the filtrate was collected by filtration, ethyl acetate (300 mL) was added to the filtrate, and it was washed once with saturated ammonium chloride aqueous solution (100 mL) and saturated sodium chloride aqueous solution (100 mL) respectively. The organic phase was dried, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 2.85 g of compound 3-6.

[0343] MS (ESI, [MH] - )m / z:290.97.

[0344] Step G: Preparation of Compound 3-7

[0345] Take a 100mL three-necked flask and add compound 3-6 (2.65g), methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.75g), 1,4-dioxane (30mL), (tributyltin) methanol (5.81g) in sequence. After the addition, place in an oil bath and heat to 100℃ for reaction under nitrogen replacement protection. After the reaction is completed, concentrate and purify by column chromatography (dichloromethane: methanol = 20:1) to obtain compound 3-7.

[0346] MS (ESI, [M+H] + )m / z:245.23.

[0347] Step H: Preparation of Compound 3-8

[0348] Take a 100mL single-mouth bottle and add compound 3-7 (1.25g), acetonitrile (20mL), and 2-iodoacylbenzoic acid (4.3g) in sequence. After the addition, replace with nitrogen and place in an oil bath and heat to 80°C for reaction. After the reaction is completed, filter, concentrate, and purify by column chromatography (dichloromethane: methanol = 20:1) to obtain compound 3-8.

[0349] MS (ESI, [MH] - )m / z:241.18.

[0350] Step I: Preparation of compound 3

[0351] Referring to the method of step D of Example 1, compound 3 was prepared by reacting compound 3-8 with compound 3-3.

[0352] 1 H NMR (500 MHz, DMSO-d 6 )δ12.41(s,1H),8.57(d,J=1.3Hz,1H),8.39(s,1H),8.22(d,J=4.8Hz,1H),7.85–7.65(m,2 H),7.30–7.09(m,1H),4.55(s,1H),4.16(d,J=14.3Hz,1H),3.59–3.45(m,J=10.5Hz,3H),3 .29(d,J=6.3Hz,1H),2.81–2.73(m,J=20.7,6.6Hz,4H),2.28–2.19(m,J=16.8,9.3Hz,1H), 2.19–2.09(m,1H),2.08–2.00(m,J=12.8,5.0Hz,1H),1.91–1.80(m,1H),1.43–1.32(m,1H).

[0353] HRMS (ESI, [M+H] + )m / z:491.18144.

[0354] Example 4: Preparation of Compound 4

[0355]

[0356] Step A: Preparation of Compound 4-1

[0357] In a 250 mL single-mouth bottle, compound 2,6-difluoronitrobenzene (15 g), concentrated sulfuric acid (100 mL) and N-bromosuccinimide (17.62 g) were added in sequence. The mixture was stirred at 80 ° C overnight under nitrogen protection. After the reaction was completed, the reaction solution was poured into ice water and extracted three times with ethyl acetate (200 mL). The organic phase was dried and purified by column chromatography (petroleum ether: ethyl acetate = 20:1) to obtain 17.63 g of compound 4-1.

[0358] Step B: Preparation of compound 4-2

[0359] Compound 4-1 (17.63 g), N,N-dimethylformamide (150 mL) and DL-2-aminobutyric acid methyl ester hydrochloride (12.52 g) were added to a 250 mL single-mouth bottle. The reaction system was transferred to an ice-salt bath, and N,N-diisopropylethylamine (28.7 g) was slowly added dropwise. After the addition was completed, the mixture was stirred overnight at room temperature. After the reaction was completed, the solvent was concentrated and removed, and the crude product was redissolved in ethyl acetate, washed with saturated brine, dried, and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 13 g of compound 4-2.

[0360] MS (ESI, [MH] - )m / z:333.07.

[0361] Step C: Preparation of Compound 4-3

[0362] Compound 4-2 (12 g), methanol (150 mL), iron powder (10 g) and acetic acid (10.75 g) were added to a 500 mL single-mouth bottle. The reaction system was transferred to 70 ° C and stirred for 1 h. After the reaction was completed, the reaction solution was filtered, concentrated, washed with saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate, dried, and purified by column chromatography (petroleum ether: ethyl acetate = 3:1 as mobile phase) to obtain 9 g of compound 4-3.

[0363] MS (ESI, [MH] - )m / z:271.06.

[0364] Step D: Preparation of compound 4-4

[0365] Compound 4-3 (8.73 g), dichloromethane (250 mL) and 2,3-dichloro-5,6-dicyanobenzoquinone (9.43 g) were added to a 500 mL single-mouth bottle. The reaction system was stirred for 2 h at room temperature. After the reaction was completed, the solvent was concentrated and removed. Saturated sodium bicarbonate aqueous solution (300 mL) was added to the crude product and stirred overnight at room temperature. The filter cake was collected by filtration and dried to obtain 8 g of compound 4-4.

[0366] MS (ESI, [MH] - )m / z:269.06.

[0367] Step E: Preparation of Compound 4-5

[0368] Referring to the method of step G of Example 3, compound 4-4 was reacted with (tributyltin)methanol to prepare compound 4-5.

[0369] MS (ESI, [M+H] + )m / z:223.18.

[0370] Step F: Preparation of Compound 4-6

[0371] Referring to the method of step H in Example 3, compound 4-5 was reacted with 2-iodoacylbenzoic acid to prepare compound 4-6.

[0372] MS (ESI, [MH] - )m / z:219.15.

[0373] Step G: Preparation of Compound 4

[0374] Referring to the method of step D of Example 1, compound 4 was prepared by reacting compound 4-6 with compound 1-3.

[0375] 1 H NMR (500 MHz, DMSO-d 6 )δ12.40(s,1H),8.33–8.24(m,J=4.6Hz,1H),7.88(d,J=2.7Hz,1H),7.78(d,J=8.7Hz,1H),7.53(d,J=8.3Hz,1H),7.33–7.24(m,J=7.7H z,1H),7.02–6.95(m,J=8.8,2.8Hz,1H),4.41–4.29(m,J=11.7,5.8Hz,1H),4.05(d,J=13.4Hz,1H),3.61(d,J=13.4Hz,1H),3.55–3.46( m,J=8.5Hz,1H),3.42–3.35(m,J=9.7,6.4Hz,1H),3.28(d,J=6.0Hz,1H),2.86–2.79(m,3H),2.77(d,J=4.8Hz,3H),2.34–2.25(m,2H),2 .13–2.04(m,J=12.9,5.9Hz,1H),1.92–1.81(m,J=8.4,7.2Hz,1H),1.37–1.27(m,J=16.4,9.9,6.2Hz,1H),1.26–1.17(m,J=7.4Hz,3H).

[0376] HRMS (ESI, [M+H] + )m / z:451.2255

[0377] Example 5: Preparation of Compound 5

[0378]

[0379] Step A: Preparation of Compound 5

[0380] Referring to the method of step D of Example 1, compound 5 was prepared by reacting compound 3-8 with compound 1-3.

[0381] 1 H NMR (500 MHz, DMSO-d 6)δ12.42(s,1H),8.58(d,J=1.4Hz,1H),8.39(s,1H),8.29(q,J=4.6Hz,1H),7.90(d,J=2.7Hz, 1H),7.81(d,J=8.7Hz,1H),7.73(s,1H),7.00(dd,J=8.7,2.8Hz,1H),4.43–4.32(m,1H),4.23– 4.11(m,1H),3.60–3.49(m,2H),3.49–3.41(m,1H),3.38–3.35(m,1H),2.87–2.81(m,1H),2.78 (d,J=4.8Hz,3H),2.41–2.25(m,2H),2.14–2.03(m,1H),1.96–1.81(m,1H),1.48–1.30(m,1H).

[0382] HRMS (ESI, [M+H] + )m / z:473.1909.

[0383] Example 6: Preparation of Compound 6

[0384]

[0385] Step A: Preparation of Compound 6-1

[0386] In a 250 mL single-mouth bottle, 4-bromo-2-fluoro-6-nitrotoluene (10 g), carbon tetrachloride (100 mL), N-bromosuccinimide (9.13 g) and dibenzoyl peroxide (1.04 g) were added in sequence. Under nitrogen protection, the mixture was refluxed and stirred in an oil bath at 90°C overnight. After the reaction was completed, 10 g of compound 6-1 was obtained by extraction, concentration and column chromatography (petroleum ether: ethyl acetate = 20:1).

[0387] 1 H NMR (500 MHz, DMSO-d 6 )δ8.22–8.09(m,2H),4.73(d,J=1.6Hz,2H).

[0388] Step B: Preparation of compound 6-2

[0389] Compound 6-1 (1 g), acetonitrile (15 mL), 4A molecular sieve (2.5 g) and N-methylmorpholine oxide (0.75 g) were added to a 25 mL single-mouth bottle in sequence. The mixture was stirred at room temperature for 2 h under nitrogen protection. After the reaction was completed, 0.64 g of compound 6-2 was obtained by extraction, concentration and column chromatography (petroleum ether: ethyl acetate = 5:1).

[0390] 1 H NMR (500 MHz, DMSO-d 6 )δ10.13(s,1H),8.29–8.27(m,1H),8.25(dd,J=9.5,1.7Hz,1H).

[0391] Step C: Preparation of Compound 6-3

[0392] To a 100mL three-necked flask, add anhydrous tetrahydrofuran (10mL) and sodium hydrogen (0.25g, 60% mass content) in sequence, and when no gas is generated, protect with nitrogen. Transfer the reaction system to an ice-salt bath and cool to 0-5°C. Slowly add 2-(diethoxyphosphoryl)propionic acid ethyl ester (0.92g) dropwise through a disposable syringe, and control the temperature at 0-5°C. After the dropwise addition, stir the reaction system at 0-5°C for 30min. The reaction system is slightly turbid, transfer the reaction system to 40°C and stir for 5min, and the system becomes a brown clear liquid. Transfer the reaction system to -78°C, slowly add a tetrahydrofuran solution (5mL) of compound 6-2 (0.64g), and complete the dropwise addition. Stir the reaction system at -78°C for 1h. After the reaction is completed, add 20mL of saturated aqueous ammonium chloride to the reaction system to quench the reaction. The reaction system was then extracted, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate=3:1) to obtain 0.6 g of compound 6-3.

[0393] Step D: Preparation of compound 6-4

[0394] Compound 6-3 (0.1 g), ethanol (3 mL), acetic acid (0.4 mL) and iron powder (0.16 g) were added to a 50 mL single-mouth bottle in sequence. The mixture was stirred at 80 ° C for 1 h under nitrogen protection. After the reaction was completed, the mixture was filtered, concentrated, washed with saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate, dried, and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain 0.06 g of compound 6-4.

[0395] Step E: Preparation of Compound 6-5

[0396] Compound 6-4 (0.1 g), ethanol (2 mL) and acetic acid (2 mL) were added to a 15 mL microwave tube. The reaction system was transferred to a photocatalytic synthesizer and stirred at room temperature for 24 h at a wavelength of 450 nM. When the reaction was complete, the target compound precipitated in the reaction system. 0.04 g of compound 6-5 was obtained by direct filtration and drying.

[0397] Step F: Preparation of Compound 6-6

[0398] Referring to the method of step G of Example 3, compound 6-5 was reacted with (tributyltin)methanol to prepare compound 6-6.

[0399] MS (ESI, [M+H] + )m / z:208.19.

[0400] Step G: Preparation of Compound 6-7

[0401] Referring to the method of step H in Example 3, compound 6-6 was reacted with 2-iodoacylbenzoic acid to prepare compound 6-7.

[0402] MS (ESI, [M+H] + )m / z:206.16.

[0403] Step H: Preparation of Compound 6

[0404] Referring to the method of step D of Example 1, compound 6 was prepared by reacting compound 6-7 with compound 3-3.

[0405] 1 H NMR (500 MHz, DMSO-d 6 )δ11.87(s,1H),8.30–8.17(m,J=4.2Hz,1H),7.81(s,1H),7.79–7.72(m,J=8.1,1.3Hz,1H),7.27–7.1 8(m,J=10.4,8.4Hz,1H),7.11(s,1H),6.95(d,J=10.8Hz,1H),4.53(s,1H),4.02(d,J=13.9Hz,1H),3. 59–3.42(m,2H),3.36(d,J=13.9Hz,1H),3.22(d,J=5.8Hz,1H),2.86–2.69(m,J=20.9,6.5Hz,4H),2.2 4–2.12(m,2H),2.10(s,3H),2.03–1.92(m,J=12.8,5.3Hz,1H),1.88–1.76(m,1H),1.44–1.30(m,1H).

[0406] HRMS (ESI, [M+H] + )m / z:454.2058.

[0407] Example 7: Preparation of Compound 7

[0408]

[0409] Step A: Preparation of Compound 7-1

[0410] Take a 100 mL single-mouth bottle, add 1H-pyrrole-2-carboxylic acid methyl ester (0.526 g), 5-bromo-1,2-difluoro-3-nitrobenzene (1 g), potassium carbonate (1.161 g), acetonitrile (40 mL), and stir overnight at 80°C. After the reaction is completed, add ethyl acetate directly for extraction, wash with water, dry and spin dry, and obtain 1.2 g of compound 7-1 by column chromatography (petroleum ether: ethyl acetate = 5:1).

[0411] MS (ESI, [M+H] + )m / z:343.08.

[0412] Step B: Preparation of compound 7-2

[0413] Take a 250mL single-mouth bottle, add compound 7-1 (1.2g), acetic acid (3.15g, 3.00ml), iron powder (0.586g), methanol (40mL), and stir at 80°C for 2h. After the reaction is completed, filter directly, and the filtrate is directly sanded, and 0.8g of compound 7-2 is obtained by column chromatography (petroleum ether: ethyl acetate = 1:2).

[0414] Step C: Preparation of Compound 7-3

[0415] Referring to the method of step G of Example 3, compound 7-2 was reacted with (tributyltin)methanol to prepare compound 7-3.

[0416] MS (ESI, [M+H] + )m / z:233.21.

[0417] Step D: Preparation of compound 7-4

[0418] Referring to the method of step H in Example 3, compound 7-3 was reacted with 2-iodoacylbenzoic acid to prepare compound 7-4.

[0419] MS (ESI, [M+H] + )m / z:231.17.

[0420] Step E: Preparation of Compound 7

[0421] Referring to the method of step D of Example 1, compound 7 was prepared by reacting compound 7-4 with compound 3-3.

[0422] 1 H NMR (500 MHz, DMSO-d 6)δ11.41(s,1H),8.22(q,J=4.6Hz,1H),8.03–7.93(m,1H),7.77(dd,J=8.1,1.7Hz,1H),7.23(dd,J=10.5,8.3H z,1H),7.15(s,1H),7.10(t,J=8.4Hz,2H),6.71(dd,J=3.8,2.9Hz,1H),4.54(s,1H),4.00(d,J=13.8Hz,1H),3. 61–3.45(m,2H),3.35(d,J=13.8Hz,1H),3.25–3.21(m,1H),2.81(t,J=8.1Hz,1H),2.75(d,J=4.8Hz,3H),2.24 –2.17(m,1H),2.13(dd,J=12.8,7.2Hz,1H),2.01(dd,J=12.8,5.3Hz,1H),1.89–1.78(m,1H),1.44–1.33(m,1H)

[0423] HRMS (ESI, [M+H] + )m / z:479.2008.

[0424] Example 8: Preparation of Compound 8

[0425]

[0426] Step A: Preparation of Compound 8-1

[0427] Take a 100mL single-mouth bottle, add methyl 3-amino-4-bromobenzoate (1g), acetonitrile (20mL), cesium carbonate (2.83g) and bis(triphenylphosphine)palladium dichloride (II) (3.05) in sequence. Heat the mixture to 80°C under nitrogen protection, dissolve (1-(tert-butoxycarbonyl)-1H-pyrrol-2-yl)boric acid (1.1g) in 10mL acetonitrile, and slowly add it dropwise to the above reaction system, adding it in about 0.5h. After the addition, the reaction system is stirred at 100°C overnight. After the reaction is completed, the reaction solution is directly sanded and purified by column chromatography (dichloromethane: methanol = 20:1) to obtain 0.6g of compound 8-1.

[0428] MS (ESI, [M+H] + )m / z:243.22.

[0429] Step B: Preparation of compound 8-2

[0430] Take a 50mL single-mouth bottle, add compound 8-1 (500mg) and anhydrous tetrahydrofuran (10mL) in sequence. Under nitrogen protection, transfer the reaction system to an ice-salt bath, slowly drop 2.5M lithium aluminum hydride tetrahydrofuran solution (2.5mL), and keep warm for 0.5h. After the reaction is completed, add water to quench, add silica gel sand, and purify by column chromatography (dichloromethane: methanol = 10:1) to obtain compound 8-2.

[0431] MS (ESI, [M+H] + )m / z:215.24.

[0432] Step C: Preparation of Compound 8-3

[0433] Referring to the method of step H in Example 3, compound 8-2 was reacted with 2-iodoacylbenzoic acid to prepare compound 8-3.

[0434] MS (ESI, [MH] - )m / z:211.19.

[0435] Step D: Preparation of Compound 8

[0436] Referring to the method of step D of Example 1, compound 8 was prepared by reacting compound 8-3 with compound 3-3.

[0437] 1 H NMR (500 MHz, DMSO-d 6 )δ11.41(s,1H),8.39–8.10(m,1H),7.85(d,J=8.0Hz,1H),7.77(dd,J=8.1,1.4Hz,1H),7.57(dd,J=2.9,1.3Hz,1H),7 .36–7.06(m,3H),6.96(dd,J=3.4,1.3Hz,1H),6.66(t,J=3.3Hz,1H),4.63–4.44(m,1H),4.01(d,J=13.5Hz,1H),3.57 –3.42(m,2H),3.36(d,J=13.5Hz,1H),3.21(t,J=5.8Hz,1H),2.80(t,J=8.1Hz,1H),2.75(t,J=6.8Hz,3H),2.19(dt,J =16.7,8.2Hz,1H),2.15–2.05(m,1H),2.00(dd,J=12.7,5.3Hz,1H),1.82(dt,J=10.4,6.4Hz,1H),1.43–1.30(m,1H).

[0438] HRMS (ESI, [M+H] +)m / z:461.2099.

[0439] Test Example 1 PARP protein inhibitory activity

[0440] 1.1 PARP1 protein activity assay

[0441] A chemiluminescent assay kit (BPS, catalog number 80551) was used. 50 μL of 1× histone was added to a 96-well plate and incubated overnight at 4°C. 200 μL of PBST buffer (containing 0.05% Tween-20) was added to each well and washed three times, the liquid in the well plate was removed, 200 μL of blocking buffer 3 was added, and the well plate was blocked for 60-90 min at room temperature, the blocking solution was discarded, and the PBST buffer was washed three times to remove the liquid in the well plate. 25 μL of the master mixture (2.5 μL 10x PARP buffer + 2.5 μL 10x biotinylated substrate analysis mixture + 5 μL activated DNA (5×) + 15 μL water) and 5 μL 1x PARP buffer were added to each well, and the compound group was sprayed with the compound using a nanoliter pipette. 20 μL of 1x PARP buffer was added to the blank control group, and 20 μL of PARP1 enzyme (2.4 ng / mL) was added to the other wells to start the reaction and incubate at room temperature for 1 hour. Add 50 μL of streptavidin-HRP (diluted 1:50 in blocking buffer 3) to each well and incubate at room temperature for 30 min. Wash three times with PBST to remove the liquid in the well plate. Before use, mix 50 μL of ELISA ECL substrate A and 50 μL of ELISA ECL substrate B on ice and add 100 μL to each well. Detect the absorbance value with PerkinElmer Envision microplate reader LUMINESCENCE, perform four-parameter analysis, fit the dose-effect curve, and calculate IC 50 .

[0442] 1.2 PARP2 protein activity assay

[0443] A chemiluminescent assay kit (BPS, Cat. No. 80552) was used. 50 μL of 1× histone was added to a 96-well plate and incubated overnight at 4°C. 200 μL of PBST buffer (containing 0.05% Tween-20) was added to each well and washed three times, the liquid in the well plate was removed, 200 μL of blocking buffer 3 was added, and the well plate was blocked at room temperature for 60-90 min, the blocking solution was discarded, and the PBST buffer was washed three times to remove the liquid in the well plate. 25 μL of the master mixture (2.5 μL 10x PARP buffer + 2.5 μL 10x biotinylated substrate assay mixture + 5 μL activated DNA (5x) + 10 μL water + 5 μL 5mM DTT) and 5 μL 1x PARP buffer (containing DTT at a final concentration of 1.25 mM) were added to each well, and the compound group was sprayed with the compound using a nanoliter pipette. 20 μL 1x PARP buffer (containing DTT at a final concentration of 1.25 mM) was added to the blank control group, and 20 μL PARP2 enzyme (2 ng / mL) was added to other wells to start the reaction and incubate at room temperature for 1 hour. 50 μL streptavidin-HRP (blocking buffer 3 diluted 1:50) was added to each well and incubated at room temperature for 30 min. Wash three times with PBST to remove the liquid in the well plate. Before use, 50 μL ELISA ECL substrate A and 50 μL ELISA ECL substrate B were mixed on ice and 100 μL was added to each well. The absorbance value was detected by PerkinElmer Envision microplate reader LUMINESCENCE, four-parameter analysis was performed, the dose-effect curve was fitted, and the IC 50 , the results are shown in Table 1.

[0444] Table 1 PARP1 and PARP2 protein activity assay results of the compounds

[0445]

[0446] Test Example 2 In vitro cell proliferation inhibitory activity

[0447] 2.1 MDA-MB-436 cell proliferation inhibitory activity assay

[0448] MDA-MB-436 cells in good growth state were collected into centrifuge tubes and the cell density was adjusted to 2×10 in complete medium (DMEM high glucose + 10% FBS + 1× insulin-transferrin-selenium (ITS-G) + 16 μg / mL reduced glutathione). 4 / mL, inoculated on a 96-well plate (100μL / well), after overnight culture in a cell culture incubator, use a pipette to add compounds to a final concentration of 400nM-0.02nM, 2 replicates, and set up controls. After continuing to culture in the cell culture incubator for 168 hours, add the detection reagent CCK-8 (manufacturer: Beijing Tongren Chemical, 10μL / well), incubate in the cell culture incubator for 1.5 hours, and detect its absorbance at 450nm using a PerkinElmer Envision microplate reader. Four-parameter analysis, fitting of the dose-effect curve, and calculation of IC 50 , the results are shown in Table 2, where A represents: IC 50 Value ≤100nM.

[0449] Table 2 Results of DA-MB-436 cell proliferation inhibition activity of compounds

[0450]

[0451]

[0452] Test Example 3 In vitro pharmacokinetics

[0453] 3.1 In vitro liver microsome stability test

[0454] The liver microsome incubation sample was prepared by mixing PBS buffer (pH 7.4), liver microsome solution (0.5 mg / mL), test compound and NADPH+MgCl 2 The solution was incubated at 37°C and 300 rpm for 1 hour. The 0-hour sample was prepared by mixing PBS buffer (pH 7.4), liver microsome solution (0.5 mg / mL), and the test compound. The sample was added with acetonitrile solution containing internal standard to prepare the supernatant by protein precipitation, which was diluted for LC / MS / MS determination.

[0455] The compounds of the present application have good liver microsome stability.

[0456] Test Example 4 In vivo pharmacokinetics

[0457] 4.1 Pharmacokinetics in mice

[0458] ICR mice weighing 24-27 g were randomly divided into intravenous injection group (n=6) and oral gavage group (n=3) after acclimation for 3-5 days. The Example solution was injected intravenously at a dose of 0.1 mg / kg and gavaged orally at a dose of 0.1 mg / kg, respectively.

[0459] Blood was collected from the eye sockets at 0, 0.083 (5 min), 0.25 (15 min), 0.5 (30 min), 2, 4, 8, and 24 h after intravenous injection to prepare plasma samples. Blood was collected from the eye sockets at 0, 0.25 (15 min), 2, 8, and 24 h after intragastric administration to prepare plasma samples.

[0460] 30 μL of plasma sample and standard curve sample were taken, and acetonitrile solution containing internal standard was added to obtain supernatant after protein precipitation, which was diluted for LC / MS / MS determination. Non-compartmental model fitting was used to calculate relevant pharmacokinetic parameters.

[0461] 4.2 Pharmacokinetics in rats

[0462] SD rats weighing 200-240 g were randomly divided into groups after acclimation for 3-5 days, with 3 rats in each group, and the Example solution was administered intravenously at a dose of 0.1 mg / kg or orally at a dose of 0.5 mg / kg.

[0463] Blood was collected from the eye sockets at 0, 0.083 (5 min), 0.25 (15 min), 0.5 (30 min), 1, 2, 4, 6, 8, 10, and 24 h after intravenous injection to prepare plasma samples. Blood was collected from the eye sockets at 0, 0.25 (15 min), 0.5 (30 min), 1, 2, 4, 6, 8, 10, and 24 h after intragastric administration to prepare plasma samples.

[0464] 30 μL of plasma sample and standard curve sample were taken, and acetonitrile solution containing internal standard was added to obtain supernatant after protein precipitation, which was diluted for LC / MS / MS determination. Non-compartmental model fitting was used to calculate relevant pharmacokinetic parameters.

[0465] The compounds of the present application have good in vivo pharmacokinetic properties.

Claims

1. A compound of formula (IA), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, in, " ” is selected from a single bond or a double bond; X 1 Selected from CR a , N or NR a’ ; X 2 Selected from CR b or N; X 3 and X 4 Each independently selected from CR c or N; R a , R b and R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH2) n R al 、-(CH2) n OR al 、-(CH2) n C(O)R al 、-(CH2) n C(O)OR al 、-(CH2) n S(O) m R al 、-(CH2) n NR a2 R a3 、-(CH2) n NR a2 C(O)OR a3 、-(CH2) n NR a2 C(O)(CH2) nl R a3 、-(CH2) n NR a2 C(O)NR a2 R a3 、-(CH2) n C(O)NR a2 (CH2) nl R a3 、-OC(R al R a2 ) n (CH2) nl R a3 or -(CH2) n NR a2 S(O) m R a3 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted; Y is selected from CR 1 or NR a’ ; R a’ is selected from hydrogen, alkyl, cycloalkyl or heterocycloalkyl, wherein the alkyl, cycloalkyl or heterocycloalkyl may be further substituted; Or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and together with the atoms to which they are attached form a heterocyclenyl or heteroaryl group, which may be further optionally substituted; Or, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and together with the atoms to which they are attached form a heterocyclenyl or heteroaryl group, which may be further optionally substituted; R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH2) n R 1l 、-(CH2) n OR 1l 、-(CH2) n C(O)R 1l 、-(CH2) n C(O)OR 1l 、-(CH2) n S(O) m R 1l 、-(CH2) n NR 12 R 13 、-(CH2) n NR 12 C(O)OR 13 、-(CH2) n NR 12 C(O)(CH2) nl R 13 、-(CH2) n NR 12 C(O)NR 12 R 13 、-(CH2) n C(O)NR 12 (CH2) nl R 13 、-OC(R 1l R 12 ) n (CH2) nl R 13 or -(CH2) n NR 12 S(O) m R 13 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted; Or, R 1 and R a and together with the atoms to which they are attached form a cycloalkenyl, heterocycloalkenyl, aryl or heteroaryl group, which may be further optionally substituted; Ring A is a heterocyclyl, aryl or heteroaryl group; R 2 is selected from deuterium, halogen, nitro, hydroxy, amino, mercapto, oxo, cyano, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -(CH2) n R 2l 、-(CH2) n OR 2l 、-(CH2) n C(O)R 2l 、-(CH2) n C(O)OR 2l 、-(CH2) n S(O) m R 2l 、-(CH2) n NR 22 R 23 、-(CH2) n NR 22 C(O)OR 23 、-(CH2) n NR 22 C(O)(CH2) nl R 23 、-(CH2) n NR 22 C(O)NR 22 R 23 、-(CH2) n C(O)NR 22 (CH2) nl R 23 、-OC(R 2l R 22 ) n (CH2) nl R 23 or -(CH2) n NR 22 S(O) m R 23 , the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group may be further substituted; R a1 , R a2 , R a3 , R 11 , R 12 , R 13 , R 21 , R 22 , R 23 Each is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be further substituted; R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxy, amino, mercapto, cyano, alkyl, alkoxy, alkenyl or alkynyl, which may be further substituted; or R 3 and R 4 Together they form = O; p is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; n or n1 is each independently selected from 0, 1, 2, 3 or 4.

2. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein " " is selected from a double bond, X 1 Selected from CR a or N, Y selected from CR 1 ; Optionally, X 1 Selected from CR a ; or, X 1 is selected from CH; or, X 1 Selected from N; Optionally, X 2 Selected from CR b ; or, X 2 is selected from CH or C(F); or, X 2 Selected from N; Optionally, X 3 and X 4 are each independently selected from CH or N; Optionally, R a is selected from hydrogen or halogen; Optionally, R b is selected from hydrogen or halogen; Optionally, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a 5-membered heteroaryl group; or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached together form a pyrrolyl, pyrazolyl or imidazolyl group; or, X 1 Selected from CR a , Y is selected from NR a’ , and R a’ and R a and the atoms to which they are attached form Optionally, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached together form a 5-membered heteroaryl group; or, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and together with the atoms to which they are attached, form a pyrrolyl, pyrazolyl or imidazolyl group; Or, X 1 Selected from NR a’ , Y is selected from CR 1 , R 1 and R a’ and the atoms to which they are attached form 3. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, mercapto, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH2) n R 1l 、-(CH2) n OR 1l 、-(CH2) n C(O)R 1l 、-(CH2) n C(O)OR 1l 、-(CH2) n S(O) m R 1l 、-(CH2) n NR 12 R 13 、-(CH2) n NR 12 C(O)OR 13 、-(CH2) n NR 12 C(O)(CH2) nl R 13 、-(CH2) n NR 12 C(O)NR 12 R 13 、-(CH2) n C(O)NR 12 (CH2) nl R 13 、-OC(R 1l R 12 ) n (CH2) nl R 13 or -(CH2) n NR 12 S(O) m R 13 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R bb replace; Or, R 1 Selected from hydrogen, deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the amino, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R bb replace; Or, R 1 Selected from C 1-3 Alkyl or C 3-6 Cycloalkyl, the C 1-3 Alkyl or C 3-6 The cycloalkyl group may be further optionally substituted with one or more R bb replace; Or, R 1 is selected from methyl, ethyl or cyclopropyl, wherein the methyl, ethyl or cyclopropyl group may be further optionally substituted by one or more R bb replace; Or, R 1 Selected from methyl, trifluoromethyl, ethyl, cyclopropyl; Optionally, R bb Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxyl, amino or cyano; Or, R bb is selected from deuterium, halogen or hydroxyl; Or, R bb Selected from F; Optionally, R 1 and R a and the atoms to which they are attached together to form C 5-6 Cycloalkenyl, the C 5-6 The cycloalkenyl group may be further optionally substituted with one or more R cc replace; Or, R 1 and R a and the atoms to which they are attached together form a cyclopentenyl or cyclohexenyl group, which may optionally be further substituted by one or more R cc replace; Or, R 1 With R a and the atoms to which they are attached form Optionally, R cc Selected from deuterium, halogen or hydroxyl.

4. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein ring A is a 6-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Alternatively, Ring A is a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; Alternatively, Ring A is furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl; Alternatively, Ring A is pyridyl.

5. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, -(CH2) n R 2l 、-(CH2) n OR 2l 、-(CH2) n C(O)R 2l 、-(CH2) n C(O)OR 2l 、-(CH2) n S(O) m R 2l 、-(CH2) n NR 22 R 23 、-(CH2) n NR 22 C(O)OR 23 、-(CH2) n NR 22 C(O)(CH2) nl R 23 、-(CH2) n NR 22 C(O)NR 22 R 23 、-(CH2) n C(O)NR 22 (CH2) nl R 23 、-OC(R 2l R 22 ) n (CH2) nl R 23 or -(CH2) n NR 22 S(O) m R 23 , the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl may be further optionally substituted by one or more R dd replace; Or, R 2 Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, -(CH2) n C(O)OR 2l 、-(CH2) n NR a2 C(O)(CH2) nl R 23 or -(CH2) n C(O)NR 22 (CH2) nl R 23 , the amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The cycloalkyl or 3-6 membered heterocycloalkyl group may be further optionally substituted with one or more R dd replace; Or, R 2 Selected from halogen, C 1-3 Alkyl, C 1-3 Alkoxy or -(CH2) n C(O)NR 22 (CH2) nl R 23 , the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more R dd replace; Or, R 2 Selected from halogen, C 1-3 Alkyl, C 1-3 Alkoxy or -C(O)NR 22 R 23 , the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more deuterium, halogen or hydroxyl groups; Or, R 2 Selected from fluorine, methyl, -OCH3 or -C(O)NHCH3; Optionally, p is selected from 1, 2 or 3; or, p is selected from 1 or 2; m is selected from 1 or 2; n or n1 is each independently selected from 0, 1 or 2; or, n or n1 is each independently selected from 0 or 1.

6. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, amino, thiol, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl or C 2-4 Alkynyl, The amino group, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-4 Alkenyl or C 2-4 The alkynyl group may be further optionally substituted with one or more R ff replace; Or, R 3 and R 4 are each independently selected from hydrogen, deuterium, hydroxy, amino, methyl or methoxy; Or, R 3 and R 4 are all selected from hydrogen; Optionally, R ff Selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 The alkoxy group may optionally be further substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino or cyano.

7. The compound of formula (IA) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, which is selected from the compound of formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof, Alternatively, it is selected from the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), the compound of formula (IIA), the compound of formula (IIIA), the compound of formula (IVA), the compound of formula (VA), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, in, R 1 , R 2 , X 1 , X 2 , X 3 , X 4 and n is as defined in claim 1; Ring B is selected from 5-6 membered heteroaryl, the 5-6 membered heteroaryl is optionally substituted by one or more R cc replace.

8. The following compound, its stereoisomer or its pharmaceutically acceptable salt:

9. A pharmaceutical composition comprising the compound according to any one of claims 1 to 8, its stereoisomer or a pharmaceutically acceptable salt thereof.

10. Use of the compound according to any one of claims 1 to 8, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating a disease associated with PARP; optionally, the disease associated with PARP is selected from tumors, cancers, ischemic diseases or neurodegenerative diseases.

Citation Information

Cited By

  • Pyridine derivative and application thereof in medicine

    CN116867784A

  • Pyridine derivatives and their use in medicine

    CN116867784B